Trials / Completed
CompletedNCT02112526
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acalabrutinib |
Timeline
- Start date
- 2014-08-07
- Primary completion
- 2020-06-30
- Completion
- 2024-10-04
- First posted
- 2014-04-14
- Last updated
- 2024-12-20
- Results posted
- 2020-07-29
Locations
7 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT02112526. Inclusion in this directory is not an endorsement.